Tan, Eng Huat

Erlotinib in Previously Treated Non–Small-Cell Lung Cancer

Shepherd, F. A., Rodrigues Pereira, J., Ciuleanu, T., Tan, E. H., Hirsh, V., Thongprasert, S., Campos, D., Maoleekoonpiroj, S., Smylie, M., Martins, R., et al. (2005) · New England Journal of Medicine

Lung Cancer Treatments and MutationsLung Cancer Diagnosis and Treatment

Cited by 5,419

Bystander CD8+ T cells are abundant and phenotypically distinct in human tumour infiltrates

Simoni, Y., Becht, E., Fehlings, M., Loh, C. Y., Koo, S.-L., Teng, K. W. W., Yeong, J. P. S., Nahar, R., Zhang, T., Kared, H., et al. (2018) · Nature

Cancer Immunotherapy and BiomarkersT-cell and B-cell Immunology

Cited by 1,370

Lorlatinib in patients with ALK-positive non-small-cell lung cancer: results from a global phase 2 study

Solomon, B. J., Besse, B., Bauer, T. M., Felip, E., Soo, R. A., Camidge, D. R., Chiari, R., Bearz, A., Lin, C.-C., Gadgeel, S. M., et al. (2018) · The Lancet Oncology

Lung Cancer Treatments and MutationsLung Cancer Research Studies

Cited by 791

Durvalumab as third-line or later treatment for advanced non-small-cell lung cancer (ATLANTIC): an open-label, single-arm, phase 2 study

Garassino, M. C., Cho, B.-C., Kim, J.-H., Mazières, J., Vansteenkiste, J., Lena, H., Corral Jaime, J., Gray, J. E., Powderly, J., Chouaid, C., et al. (2018) · The Lancet Oncology

Cancer Immunotherapy and BiomarkersLung Cancer Treatments and Mutations

Cited by 568

A common BIM deletion polymorphism mediates intrinsic resistance and inferior responses to tyrosine kinase inhibitors in cancer

Ng, K. P., Hillmer, A. M., Chuah, C. T. H., Juan, W. C., Ko, T. K., Teo, A. S. M., Ariyaratne, P. N., Takahashi, N., Sawada, K., Fei, Y., et al. (2012) · Nature Medicine

Cell death mechanisms and regulationLung Cancer Treatments and Mutations

Cited by 557

Examining Treatment Outcomes with Erlotinib in Patients with Advanced Non–Small Cell Lung Cancer Whose Tumors Harbor Uncommon EGFR Mutations

Klughammer, B., Brugger, W., Cappuzzo, F., Ciuleanu, T., Mok, T., Reck, M., Tan, E. H., Delmar, P., Klingelschmitt, G., Yin, A.-Y., et al. (2016) · Journal of Thoracic Oncology

Lung Cancer Treatments and MutationsHER2/EGFR in Cancer Research

Cited by 98

Bosutinib inhibits migration and invasion via ack1 in kras mutant non-small cell lung cancer

Tan, D. S., Haaland, B., Gan, J. M., Tham, S. C., Sinha, I., Tan, E. H., Lim, K. H., Takano, A., Krisna, S. S., Thu, M. M. M., et al. (2014) · Molecular Cancer

Lung Cancer Treatments and MutationsProtein Kinase Regulation and GTPase Signaling

Cited by 59

Intertumor heterogeneity of non-small-cell lung carcinomas revealed by multiplexed mutation profiling and integrative genomics

Tan, D. S. W., Camilleri‐Broët, S., Tan, E. H., Alifano, M., Lim, W., Bobbio, A., Zhang, S., Ng, Q., Ang, M., Iyer, N. G., et al. (2014) · International Journal of Cancer

Lung Cancer Treatments and MutationsCancer Genomics and Diagnostics

Cited by 43

Impact of Smoking and Brain Metastasis on Outcomes of Advanced EGFR Mutation Lung Adenocarcinoma Patients Treated with First Line Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors

Jain, A., Lim, C., Gan, E. M., Ng, D. Z., Ng, Q. S., Ang, M. K., Takano, A., Chan, K. S., Tan, W. M., Kanesvaran, R., et al. (2015) · PLOS ONE

Lung Cancer Treatments and MutationsLung Cancer Diagnosis and Treatment

Cited by 32